International consensus guidance for management of myasthenia gravis: Executive summary.
OBJECTIVE: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA a...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Journal article |
| שפה: | English |
| יצא לאור: |
American Academy of Neurology
2016
|
| _version_ | 1826267363463397376 |
|---|---|
| author | Sanders, D Wolfe, G Benatar, M Evoli, A Gilhus, N Illa, I Kuntz, N Massey, J Melms, A Murai, H Nicolle, M Palace, J Richman, D Verschuuren, J Narayanaswami, P |
| author_facet | Sanders, D Wolfe, G Benatar, M Evoli, A Gilhus, N Illa, I Kuntz, N Massey, J Melms, A Murai, H Nicolle, M Palace, J Richman, D Verschuuren, J Narayanaswami, P |
| author_sort | Sanders, D |
| collection | OXFORD |
| description | OBJECTIVE: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. RESULTS: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. CONCLUSION: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide. |
| first_indexed | 2024-03-06T20:53:03Z |
| format | Journal article |
| id | oxford-uuid:383d8173-a44e-4e7b-8491-5cce5f4f5fa8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:53:03Z |
| publishDate | 2016 |
| publisher | American Academy of Neurology |
| record_format | dspace |
| spelling | oxford-uuid:383d8173-a44e-4e7b-8491-5cce5f4f5fa82022-03-26T13:49:01ZInternational consensus guidance for management of myasthenia gravis: Executive summary.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:383d8173-a44e-4e7b-8491-5cce5f4f5fa8EnglishSymplectic Elements at OxfordAmerican Academy of Neurology2016Sanders, DWolfe, GBenatar, MEvoli, AGilhus, NIlla, IKuntz, NMassey, JMelms, AMurai, HNicolle, MPalace, JRichman, DVerschuuren, JNarayanaswami, POBJECTIVE: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. RESULTS: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. CONCLUSION: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide. |
| spellingShingle | Sanders, D Wolfe, G Benatar, M Evoli, A Gilhus, N Illa, I Kuntz, N Massey, J Melms, A Murai, H Nicolle, M Palace, J Richman, D Verschuuren, J Narayanaswami, P International consensus guidance for management of myasthenia gravis: Executive summary. |
| title | International consensus guidance for management of myasthenia gravis: Executive summary. |
| title_full | International consensus guidance for management of myasthenia gravis: Executive summary. |
| title_fullStr | International consensus guidance for management of myasthenia gravis: Executive summary. |
| title_full_unstemmed | International consensus guidance for management of myasthenia gravis: Executive summary. |
| title_short | International consensus guidance for management of myasthenia gravis: Executive summary. |
| title_sort | international consensus guidance for management of myasthenia gravis executive summary |
| work_keys_str_mv | AT sandersd internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT wolfeg internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT benatarm internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT evolia internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT gilhusn internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT illai internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT kuntzn internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT masseyj internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT melmsa internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT muraih internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT nicollem internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT palacej internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT richmand internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT verschuurenj internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary AT narayanaswamip internationalconsensusguidanceformanagementofmyastheniagravisexecutivesummary |